Oberweis Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Oberweis Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17M	Buy	221,386 +32,556	+17%	+$2.54M	0.5%	75
2025 Q4	$14.9M	Buy	188,830 +49,930	+36%	+$4.32M	0.55%	73
2025 Q3	$12.7M	Hold	138,900	–	–	0.49%	77
2025 Q2	$9.06M	Buy	138,900 +73,300	+112%	+$4.77M	0.39%	92
2025 Q1	$4.39M	Hold	65,600	–	–	0.22%	143
2024 Q4	$3.63M	Buy	65,600 +22,100	+51%	+$1.27M	0.17%	157
2024 Q3	$2.6M	Hold	43,500	–	–	0.13%	177
2024 Q2	$2.77M	Hold	43,500	–	–	0.17%	158
2024 Q1	$3.01M	Hold	43,500	–	–	0.22%	151
2023 Q4	$2.4M	Buy	43,500 +10,500	+32%	+$578K	0.22%	162
2023 Q3	$1.92M	Buy	+33,000	New	+$1.9M	0.2%	162
2015 Q4	–	Sell	-158,235	Closed	-$6.25M	–	175
2015 Q3	$6.25M	Buy	158,235 +13,450	+9%	+$765K	1.82%	26
2015 Q2	$8.98M	Buy	144,785 +72,250	+100%	+$4.3M	2.38%	11
2015 Q1	$4.54M	Buy	72,535 +55,735	+332%	+$3.39M	1.27%	31
2014 Q4	$947K	Buy	+16,800	New	+$741K	0.28%	60

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

GAM

Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Oberweis Asset Management's ANIP Position: Q1 2026 in Review

Oberweis Asset Management increased its ANI Pharmaceuticals (ANIP) stake by 17% in Q1 2026, buying an estimated $2.54M and bringing the position to 221,386 shares worth $17M. The position accounts for 0.5% of the portfolio, ranked #75.

Oberweis Asset Management first reported a position in ANIP in Q4 2014 and has held it in 15 quarters since. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

Oberweis Asset Management held 221,386 shares of ANI Pharmaceuticals worth $17M as of Q1 2026.
Oberweis Asset Management bought 32,556 ANI Pharmaceuticals shares in Q1 2026, an estimated $2.54M.
ANI Pharmaceuticals made up 0.5% of Oberweis Asset Management's portfolio in Q1 2026, its #75 holding.
Oberweis Asset Management first reported a position in ANI Pharmaceuticals in Q4 2014 and has held it in 15 quarters since.
280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Oberweis Asset Management's 13F filing for Q1 2026, filed 15 May 2026.